SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18 HKD | +0.11% |
|
0.00% | +29.31% |
| Apr. 18 | Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 | MT |
| Apr. 01 | SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 4,755 | 4,996 | 10,158 | 10,158 | - |
| Enterprise Value (EV) 1 | 3,795 | 4,177 | 7,703 | 7,562 | 6,646 |
| P/E ratio | 5.3 x | 6.05 x | 7.36 x | 9.41 x | 8.77 x |
| Yield | 4.04% | 4.7% | 2.25% | 1.32% | - |
| Capitalization / Revenue | 1.89 x | 1.82 x | 2.44 x | 2.81 x | 2.49 x |
| EV / Revenue | 1.51 x | 1.52 x | 2.44 x | 2.09 x | 1.63 x |
| EV / EBITDA | 3.39 x | 3.44 x | 7.03 x | 5.74 x | 4.51 x |
| EV / FCF | 3,706,970 x | 3,546,040 x | - | - | - |
| FCF Yield | 0% | 0% | - | - | - |
| Price to Book | 1.98 x | 1.7 x | 3.08 x | 2.42 x | 1.88 x |
| Nbr of stocks (in thousands) | 674,684 | 682,330 | 609,618 | 609,618 | - |
| Reference price 2 | 7.048 | 7.322 | 16.66 | 16.66 | 16.66 |
| Announcement Date | 3/24/22 | 3/30/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,919 | 2,518 | 2,750 | 3,156 | 3,610 | 4,086 |
| EBITDA 1 | - | 1,121 | 1,213 | 1,260 | 1,319 | 1,475 |
| EBIT 1 | - | 1,013 | 1,094 | 1,215 | 1,254 | 1,382 |
| Operating Margin | - | 40.22% | 39.78% | 38.52% | 34.72% | 33.83% |
| Earnings before Tax (EBT) 1 | - | 1,026 | 940.1 | 1,217 | 1,285 | 1,417 |
| Net income 1 | - | 923.4 | 855.4 | 1,122 | 1,150 | 1,233 |
| Net margin | - | 36.66% | 31.11% | 35.55% | 31.85% | 30.17% |
| EPS 2 | 1.350 | 1.330 | 1.210 | 1.720 | 1.770 | 1.900 |
| Free Cash Flow | - | 1,024 | 1,178 | - | - | - |
| FCF margin | - | 40.65% | 42.83% | - | - | - |
| FCF Conversion (EBITDA) | - | 91.34% | 97.12% | - | - | - |
| FCF Conversion (Net income) | - | 110.87% | 137.7% | - | - | - |
| Dividend per Share 2 | - | 0.2849 | 0.3440 | 0.3750 | 0.2200 | - |
| Announcement Date | 3/25/21 | 3/24/22 | 3/30/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 960 | 819 | 1,297 | 2,595 | 3,511 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 1,024 | 1,178 | - | - | - |
| ROE (net income / shareholders' equity) | - | 70.2% | 32.2% | 30.7% | 29.7% | 24.1% |
| ROA (Net income/ Total Assets) | - | 26.6% | 20.4% | 24.5% | 25.3% | - |
| Assets 1 | - | 3,473 | 4,192 | 4,021 | 4,545 | - |
| Book Value Per Share 2 | - | 3.560 | 4.310 | 5.420 | 6.880 | 8.860 |
| Cash Flow per Share 2 | - | 1.480 | 1.670 | 1.820 | 1.710 | - |
| Capex 1 | - | 5.7 | 5.77 | 164 | 185 | - |
| Capex / Sales | - | 0.23% | 0.21% | 5.26% | 5.12% | - |
| Announcement Date | 3/25/21 | 3/24/22 | 3/30/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
16.66
CNY
Average target price
16.5
CNY
Spread / Average Target
-0.99%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.31% | 1.4B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 6600 Stock
- Financials SciClone Pharmaceuticals (Holdings) Limited
